Improvement of Quality of Life With Nocturnal Oxygen Therapy in Heart Failure Patients With Central Sleep Apnea

Background: Previously, we reported the benefit of 12 weeks of home oxygen therapy (HOT) in patients with central sleep apnea (CSA) and heart failure (HF). In the present study, we attempted to confirm the sustained efficacy of HOT in the long term treatment. Methods and Results: In the present stud...

Full description

Saved in:
Bibliographic Details
Published in:Circulation Journal 2009, Vol.73(7), pp.1255-1262
Main Authors: Sasayama, Shigetake, Izumi, Tohru, Matsuzaki, Masunori, Matsumori, Akira, Asanoi, Hidetsugu, Momomura, Shin-ichi, Seino, Yoshihiko, Ueshima, Kenji, Group, The CHF-HOT Study
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Atrial Natriuretic Factor - blood
Female
Heart failure
Heart Failure - complications
Heart Failure - physiopathology
Heart Failure - therapy
Heart Ventricles - physiopathology
Humans
Kaplan-Meier Estimate
Longitudinal Studies
Male
Middle Aged
Natriuretic Peptide, Brain - blood
Norepinephrine - blood
Oxygen
Oxygen Inhalation Therapy - methods
Prognosis
Quality of Life
Sleep apnea
Sleep Apnea, Central - complications
Sleep Apnea, Central - physiopathology
Sleep Apnea, Central - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Previously, we reported the benefit of 12 weeks of home oxygen therapy (HOT) in patients with central sleep apnea (CSA) and heart failure (HF). In the present study, we attempted to confirm the sustained efficacy of HOT in the long term treatment. Methods and Results: In the present study, 51 patients with CSA and HF (New York Heart Association (NYHA) functional classes II-III) were assigned to receive either nocturnal oxygen (HOT group n=26) or usual breathing (control group n=25) for 52 weeks. In the HOT group, greater reduction in apnea and hypopnea and greater increase in nocturnal oxygen saturation were observed. These changes were associated with greater improvement in the Specific Activity Scale (0.82 ±1.17 vs -0.11 ±0.73 Mets, P=0.009) in NYHA functional class (P=0.007) and in ejection fraction (5.45 ±11.94 vs 1.28 ±9.77%). There were no significant differences in the cardiac event rates; however, the later divergence favored the HOT group. Conclusions: The 52-week HOT was well tolerated and the benefit observed in the 12-week trial was sustained over a prolonged period of time. HOT was considered to be a valuable non-pharmacological therapeutic addition for HF patients with CSA. (Circ J 2009; 73: 1255-1262)
ISSN:1346-9843
1347-4820
DOI:10.1253/circj.CJ-08-1210